UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 72

Sortiert nach

Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06)

The lancet oncology, 2010-04, Vol.11 (4), p.350-357

2010

Volltextzugriff (PDF)

Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study

Supportive care in cancer, 2015-09, Vol.23 (9), p.2833-2840

2015

Volltextzugriff (PDF)

SEOM clinical guideline emesis (2021)

Clinical & translational oncology, 2022-04, Vol.24 (4), p.712-723

2022

Volltextzugriff (PDF)

Opioid-Induced Constipation in Oncological Patients: New Strategies of Management

Current treatment options in oncology, 2019-12, Vol.20 (12), p.91-91, Article 91

2019

Volltextzugriff (PDF)

SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan

Supportive care in cancer, 2016-01, Vol.24 (1), p.499-507

2016

Volltextzugriff (PDF)

Follow-up of cancer survivors: a shared responsibility

Medicina clinica, 2011-07, Vol.137 (4), p.163

2011

Volltextzugriff (PDF)

Management of Infection and Febrile Neutropenia in Patients with Solid Cancer

Enfermedades infecciosas y microbiologia clinica, 2017-08, Vol.35 (7), p.451

2017

Volltextzugriff (PDF)

Soporte nutricional y nutrición parenteral en el paciente oncológico: informe de consenso de un grupo de expertos

Nutrición hospitalaria : organo oficial de la Sociedad Española de Nutrición Parenteral y Enteral, 2018-02, Vol.35 (1), p.224-233

2018

Volltextzugriff (PDF)

The role of pharmacogenomics in metastatic renal cell carcinoma

Cancer and metastasis reviews, 2012-09, Vol.31 (Suppl 1), p.29-32

2012

Volltextzugriff (PDF)

Nutritional support and parenteral nutrition in cancer patients: An expert consensus report

Endocrinologia, diabetes y nutricion, 2018-03, Vol.65 Suppl 1, p.17

2018

Volltextzugriff (PDF)

SOGUG-vexillum: Phase II non-randomized clinical trial of nivolumab/ipilimumab maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS4606-TPS4606

2023

Volltextzugriff (PDF)

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

The lancet oncology, 2018-01, Vol.19 (1), p.127-138

2018

Volltextzugriff (PDF)

Abstract OT-13-04: Solti-1716. Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative advanced/metastatic breast cancer patients who have progressed on or after CDK 4/6 inhibitor treatment (TATEN trial)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.OT-13-04-OT-13-04

2021

Volltextzugriff (PDF)

Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)

British journal of cancer, 2024-02, Vol.130 (3), p.434-441

2024

Volltextzugriff (PDF)

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

The New England journal of medicine, 2020-12, Vol.383 (24), p.2345-2357

2020

Volltextzugriff (PDF)

Comprehensive molecular characterization of muscle-invasive bladder cancer (MIBC) treated with durvalumab plus olaparib in the neoadjuvant setting: Neodurvarib trial

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.546-546

2022

Volltextzugriff (PDF)

Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.5019-5019

2022

Volltextzugriff (PDF)

PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma

International journal of cancer, 2020-03, Vol.146 (5), p.1435-1444

2020

Volltextzugriff (PDF)

Single nucleotide polymorphisms (SNPs) as predictors of efficacy of cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e17582-e17582

2020

Volltextzugriff (PDF)

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

The New England journal of medicine, 2023-06, Vol.388 (22), p.2058-2070

2023

Volltextzugriff (PDF)

Correction to: SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2021)

Clinical & translational oncology, 2022-07, Vol.24 (7), p.1442-1442

2022

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(67)
Mit Volltextzugriff
(68)

Publikationsform

Artikel
(72)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(32)
Life Sciences & Biomedicine
(31)
Humans
(28)
Oncology
(25)
Female
(13)
Middle Aged
(12)
Cancer
(11)
Aged
(10)
Male
(10)
Chemotherapy
(9)
Medicine
(9)
Tumors
(9)
Breast Cancer
(8)
Medicine & Public Health
(8)
Patients
(8)
Adult
(7)
Antineoplastic Agents - Adverse Effects
(7)
Metastasis
(7)
Antineoplastic Agents - Therapeutic Use
(6)
Cancer Therapies
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06)

Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study

SEOM clinical guideline emesis (2021)

Opioid-Induced Constipation in Oncological Patients: New Strategies of Management

The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)

SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan

Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations

Follow-up of cancer survivors: a shared responsibility

Management of Infection and Febrile Neutropenia in Patients with Solid Cancer

Soporte nutricional y nutrición parenteral en el paciente oncológico: informe de consenso de un grupo de expertos

The role of pharmacogenomics in metastatic renal cell carcinoma

Nutritional support and parenteral nutrition in cancer patients: An expert consensus report

A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01)

SOGUG-vexillum: Phase II non-randomized clinical trial of nivolumab/ipilimumab maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

Abstract OT-13-04: Solti-1716. Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative advanced/metastatic breast cancer patients who have progressed on or after CDK 4/6 inhibitor treatment (TATEN trial)

Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

Comprehensive molecular characterization of muscle-invasive bladder cancer (MIBC) treated with durvalumab plus olaparib in the neoadjuvant setting: Neodurvarib trial

Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial

PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma

Single nucleotide polymorphisms (SNPs) as predictors of efficacy of cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC)

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

Correction to: SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2021)

Suchergebnisse filtern